Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:

“NSCLC and anti-EGFR treatments from the ASCO Educational Book

• Early stage-adjuvant

• Gefitinib, icotinib > high DFS, no OS benefit (ADJUVANT/CTONG 1104, IMPACT and EVIDENCE)
• Osimertinib > high DFS, OS (ADAURA)
• Ongoing trials: ADAURA2, TARGET
• Ongoing trial in neoadjuvant: NeoADAURA
  +  Anti-ALK, IO for driver mutation

• Unresectable, after defitive treatment

• Osimertinib> high PFS (LAURA, ongoing)
• Ongoing trials: PACIFIC4, HORIZON-01

• Metastatic

• 1G, 2G and new TKIs (in figures below)

• Resistance mechanisms and strategies to overcome (in figures below).”

View additional information.
Source: Erman Akkus/X